The enhanced communication with the US FDA afforded by a Breakthrough Therapy Designation (BTD) is already helping to reduce uncertainty in psychiatry R&D, and could help to produce the first new mechanisms of action in decades.
The chance for more extensive discussions with FDA during development is especially important for the many “firsts” in the pipeline,...






